Unified clinical trial software
Unified clinical trial software for cosmetics clinical trials
oomnia connects workflows across cosmetics studies, helping teams manage product testing, consumer data, and real‑world usage
INDUSTRY CONTEXT
Why cosmetics clinical trials are hard to run
Cosmetic and personal care studies present unique challenges, driven by subjective outcomes, consumer behavior, and real‑world usage conditions. Unlike traditional clinical research, results often depend on perception, consistency of application, and environmental factors.
Key execution challenges include:
Subjective assessments such as skin appearance, texture, and product experience
Variability in participant behavior and product usage
Difficulty standardizing endpoints across cosmetic and dermatological outcomes
Disconnected data from devices, imaging, surveys, and clinical assessments
Challenges in maintaining consistency across study sites and evaluators
Coordination across testing centers, at‑home use, and digital engagement tools
UNIFIED PLATFORM
Why unified clinical trial software matters for cosmetics studies
Cosmetics trials typically rely on multiple tools to manage clinical evaluations, participant feedback, imaging data, and study operations. This fragmented setup can slow down workflows, create inconsistencies, and make data harder to interpret.
A unified clinical trial platform, built as a Clinical Research Information System (CRIS), connects all study elements within a single environment.
This enables continuous data flow, better consistency, and improved oversight across cosmetic product studies.
| Area | Modular eClinical system | Unified clinical trial software (oomnia) |
|---|---|---|
| Data types | Clinical, imaging, and feedback data in separate systems | All study data unified in one environment |
| Data consistency | Variability across evaluators and participants | Standardized structures across studies |
| Reconciliation | Manual alignment of imaging, survey, and clinical data | Reduced reconciliation through shared data model |
| Monitoring | Limited visibility into product usage and results | Real‑time tracking of participant data |
| Execution | Disconnected workflows across tools and partners | Unified workflows across stakeholders |
| Data quality | Higher risk of subjective inconsistencies | Structured capture with validation rules |
| Oversight | Fragmented study visibility | Centralized, real‑time oversight |
| Scalability | Difficult to scale multi‑site studies | Scalable across regions and programs |
CRIS ARCHITECTURE
One unified clinical trial platform for cosmetics studies
oomnia brings together essential study functions into a single Clinical Research Information System (CRIS), designed to support cosmetic product testing and consumer research
Handles diverse data sources, including clinical evaluations, imaging, and consumer feedback
Shared data model aligns clinical, observational, and user‑reported data
Flexible configuration allows updates to protocols and endpoints without disruption
Replaces multiple tools with one streamlined workflow
ECOSYSTEM INTEGRATION
How oomnia fits in the cosmetics research ecosystem
oomnia acts as a central hub connecting systems and stakeholders involved in cosmetic product studies
It integrates:
KEY CAPABILITIES
Key capabilities for cosmetics clinical trials
Flexible design for cosmetic product studies
- Supports a range of study types, including controlled trials, consumer use tests, and long‑term product evaluations
- Adapts to changes in application protocols, visit schedules, or outcome measures
- Maintains consistency across sites, evaluators, and participants during updates
Consistent capture of clinical and consumer data
- Enables real‑time collection of clinical assessments, imaging data, and participant feedback
- Unifies EDC, CTMS, RTSM, ePRO/eCOA, eTMF, eSource, and eConsent within one system
- Reduces manual data alignment across imaging tools, surveys, and clinical records
Tracking product usage and participant experience
- Supports both site‑based and at‑home product usage studies
- Captures self‑reported feedback, usage patterns, and device‑generated data
- Improves adherence and data completeness through structured workflows and reminders
Centralized visibility and study analytics
- Provides dashboards across participants, sites, and study phases
- Supports monitoring of product performance, safety signals, and study progress
- Delivers structured outputs for reporting and regulatory or commercial use
Imaging and dermatological data integration
- Integrates skin imaging, dermatological assessments, and lab results
- Links product usage with measurable skin outcomes and clinical observations
- Enables a complete view of product performance across studies
Designed for cosmetic product testing and consumer studies
Unified architecture removes fragmentation across clinical, imaging, and feedback data
Flexible configuration supports evolving product claims and endpoints
Simplifies workflows across sites, participants, and partners
VALUE PROPOSITION
Why sponsors choose oomnia for cosmetics trials
Client Testimonials
Collaboration built on trust and innovation
Wemedoo's technology, expertise, and intimate engagement with our team in the development of the EDC, site/patient interface, and metric capabilities are unique. They provided insight and challenged the underlying assumptions to ensure the study's goals and objectives were clearly defined and the operating structure matched with the study's intent. Their system is not a one-size-fits-all and they adapt to the needs of the sponsor, sites, physicians, and the study requirements into a system that merges health information/data and can then become not only informative but actionable.
James Kuras
Vice President of Clinical Affairs and Operations at Centinel Spine
Wemedoo's cross-functional, integrated teams capture EDC set-up, go-live, data capture, data cleaning, and finally data analysis in a globally compliant fashion supporting trials in different geographies including the US. Their speed of addressing customer needs sets in my personal experience industry benchmark whilst keeping these data solutions lean and affordable. Besides the great proprietary systems they use, their integrated team approach with personal responsibility and honest commitment to targeting outcomes differentiates the Wemedoo team from other providers. Wemedoo only made Oxular's key initial trial, a device-drug trial possible, as based on some pre-work, the Wemedoo team could substantially adapt and update the first EDC ideas for a trial under a US FDA IND. The Wemedoo team worked extremely focused on familiarizing US trial sites and clinical CROs with the use of their system, which turned out to be a key success factor of the respective trial. The highly professional and up-to-date capabilities in data sciences were mirrored by customer-centricity and super fast timelines of integrating mandatory adaptations to the data systems.
Friedrich Asmus
Former Chief Medical Officer at OXULAR
All jobs, both large and small, are performed with the same dedication to quality, detail, innovative thinking, and rigor. It is always a pleasure to work with the Wemedoo team.
Georg Mathis, PhD
CEO at Appletree CI Group AG
Wemedoo embodies all the traits desired in a partner in the clinical trial industry – expertise, innovation, reliability, compliance, and attention to detail.
Martina Diminic Smetisko, DMD
Managing Director at Marti Farm Ltd
Their dedication to, and support of, our projects has resulted in clear quality deliverables. They are always there to answer any questions with expertise in a timely manner. I am looking forward to our next project together.
Volodymyr Stus, MD
Biopharmaceutics and Clinical Research Department Manager at Polpharma SA
Complex adaptive trials demand speed, precision, and system stability. With oomnia, Wemedoo's unified clinical trial software maintained continuous drug supply oversight, real-time data capture above 99%, and zero Randomization and Trial Supply Management (RTSM) dispensing errors throughout the study. The study reached database lock within 3 days after Last Patient Last Visit (LPLV), a direct result of integrated EDC–RTSM execution and proactive technical support. Wemedoo's technology and team responsiveness played a key role in meeting aggressive milestones.
Dhiraj Patel, Dr.
Director at Velocious Clinical Research
REGULATORY READINESS
Regulatory and data ecosystem readiness
oomnia provides a structured and compliant environment aligned with the needs of cosmetic and dermatological studies
21 CFR Part 11–compliant records
21 CFR Part 11–compliant electronic records with full audit trails for inspection-ready documentation
ICH E6(R3)–aligned oversight
ICH E6(R3)‑aligned risk‑based oversight where applicable to cosmetic and dermatological study contexts
Standardized data structures
Standardized data structures for consistent reporting and documentation across studies
Global regulatory support
Support for global regulatory and product validation processes across regions
Get Started
Simplify cosmetic product studies and testing workflows
Connect clinical evaluations, consumer feedback, and real‑world usage data to improve visibility and support more reliable study outcomes
Talk to our team